5498-31-7 Usage
Description
4-bromonaphthalen-2-ol, also known as 4-bromo-2-naphthol, is an organic compound with the molecular formula C10H7BrO. It is a white crystalline solid that is soluble in organic solvents and has a characteristic aromatic smell. 4-bromonaphthalen-2-ol is characterized by the presence of a bromine atom at the 4-position and a hydroxyl group at the 2-position of the naphthalene ring, which imparts unique chemical and physical properties to the molecule.
Uses
Used in Pharmaceutical Industry:
4-bromonaphthalen-2-ol is used as a reactant in the preparation of pyrazoles, which are inhibitors of the macrophage migration inhibitory factor (MIF). MIF is a key regulator of the immune system and has been implicated in various diseases, including autoimmune disorders, cancer, and inflammatory conditions. By inhibiting MIF, pyrazoles can potentially modulate the immune response and offer therapeutic benefits in treating these diseases.
In addition to its application in the pharmaceutical industry, 4-bromonaphthalen-2-ol may also find use in other areas, such as:
1. Chemical Synthesis:
As an intermediate in the synthesis of various organic compounds, including dyes, pigments, and other specialty chemicals.
2. Analytical Chemistry:
As a reference material or standard for the calibration of analytical instruments, such as gas chromatography and mass spectrometry, due to its well-defined chemical structure and properties.
3. Research and Development:
In academic and industrial research settings, 4-bromonaphthalen-2-ol can be used as a building block for the development of new compounds with potential applications in various fields, such as materials science, agrochemistry, and environmental science.
Check Digit Verification of cas no
The CAS Registry Mumber 5498-31-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,4,9 and 8 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 5498-31:
(6*5)+(5*4)+(4*9)+(3*8)+(2*3)+(1*1)=117
117 % 10 = 7
So 5498-31-7 is a valid CAS Registry Number.
5498-31-7Relevant articles and documents
Kras-G12C inhibitor heterocyclic compounds
-
Paragraph 0165; 0175-0178, (2021/06/23)
The invention relates to Kras-G12C inhibitor heterocyclic compounds represented by formula I, a preparation method thereof, and application of the Kras-G12C inhibitor heterocyclic compounds in prevention and treatment of tumor diseases such as lung cancer, colorectal cancer and pancreatic cancer. In the preparation process, the compounds of the general formula I are obtained through a series of reactions such as SN2 reaction, protection, coupling reaction, deprotection, condensation reaction and the like.
KRAS G12C INHIBITORS
-
, (2020/03/23)
The present invention relates to compounds that, inhibit KRas G12C, In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE
-
Paragraph 001228-001229, (2019/10/29)
The present disclosure relates to bifunctional compounds, which find utility as modulators of Kirsten rat sarcoma protein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein are treated or prevented with compounds and compositions of the present disclosure.